Clinical Trial Update: A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-0587 as a Monotherapy and in Combination With Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive and Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer [Phase 1]

View source ↗

Summary

This Phase 1 trial, sponsored by Genentech, evaluates the safety, pharmacokinetics, and activity of GDC-0587 as a monotherapy and in combination with Giredestra…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Estrogen Receptor-positive Breast Cancer

Drugs mentioned

• GDC-0587
• Giredestrant (giredestrant)

Snippet

Sponsor: Genentech, Inc. | Conditions: Breast Cancer | Phase 1 | Status: RECRUITING